EHV insertion site ORF70
OwnerAlice Mundt, Andreas Gallei +1inventors
InventorsAlice Mundt, Andreas Gallei, Kristina Rehmet
Life of this patent
Estimating the term…
Abstract
The present invention relates to the field of (vector) vaccines, and especially to the novel EHV insertion site ORF70. The present invention further concerns related expression cassettes and vectors, which are suitable to express genes of interest, especially antigen encoding sequences. The viral vectors of the present invention are useful for producing an immunogenic composition or vaccine.
Claims24
An Equid Alphaherpesvirus 1 (EHV-1) vector, strain RacH, comprising an expression cassette comprising an exogenous nucleotide sequence of interest, wherein said nucleotide sequence of interest inserted into ORF70 in an EHV-1 vector (ORF70) and operably linked to a promoter sequence, and a left ORF70 flanking region selected from the group consisting of sequences having at least 95% homology with any of SEQ ID Nos:
- 13, 15, and 17, and a right ORF70 flanking region selected from the group consisting of sequences having at least 95% homology with any of SEQ ID Nos:
- 14, 16, and 18.
An Equid Alphaherpesvirus 1 (EHV-1) vector, strain RacH, comprising an exogenous nucleotide sequence of interest, wherein said nucleotide sequence of interest is operably linked to a promoter sequence, and a left ORF70 flanking region selected from the group consisting of:
- SEQ ID NOs.:
- 13, 15, and 17, and a right ORF70 flanking region selected from the group consisting of:
- SEQ ID Nos.:
- 14, 16, and 18.
An Equid Alphaherpesvirus 1 (EHV-1) vector, strain RacH, comprising a nucleotide sequence of interest inserted into ORF70.
An Equid Alphaherpesvirus 1 (EHV-1) vector, strain RacH, comprising a first and a second nucleotide sequence or gene of interest inserted into ORF70.
Dependencies are inferred from the claim text.